Bison Capital Holding Company

Bison Capital Holding Company is a diversified investment holding firm based in Hong Kong and Beijing, focusing on the healthcare, financial services, and media industries. The company is particularly active in the life sciences sector through its strategic investments and the sponsorship of Bison Capital Acquisition Corp., which merged with Xynomic Pharmaceuticals, a clinical-stage oncology company. Bison Capital aims to bridge the gap between Chinese and international markets, providing growth capital and operational expertise to its portfolio companies. Its healthcare interests are primarily centered on innovative drug development for cancer treatment, specifically through small molecule inhibitors. The firm maintains a global perspective, facilitating cross-border collaborations and market entries for its healthcare assets. Its lead clinical asset, through its subsidiary, is abexinostat, which has reached Phase 3 trials for various oncology indications.